New Allergy Therapies To Come Of Age In 2016
This article was originally published in Scrip
2016 will be the year when researchers, allergy sufferers and investors will receive Phase III results about a potential cat allergy therapy, will find out if a merger between two allergy companies has produced an acquisitive sector leader – Stallergenes Greer PLC - and if new technologies, including a once-daily patch, are likely to benefit patients with food allergies to peanuts and dairy.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.